Evaluation of Anti-Methicillin-Resistant Staphylococcus aureus (MRSA) Prescribing Habits in Patients with a Positive MRSA Nasal Swab in the Absence of Positive Cultures
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design
2.2. Data Collection
2.3. Definitions
2.4. Statistical Analysis
3. Results
3.1. Inclusion and Exclusion
3.2. Baseline Characteristics
3.3. Duration of Anti-MRSA Therapy
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Metlay, J.P.; Waterer, G.W.; Long, A.C.; Anzueto, A.; Brozek, J.; Crothers, K.; Whitney, C.G. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am. J. Respir. Crit. Care Med. 2019, 200, e45–e67. [Google Scholar] [CrossRef] [PubMed]
- Kalil, A.C.; Metersky, M.L.; Klompas, M.; Muscedere, J.; Sweeney, D.A.; Palmer, L.B.; Brozek, J.L. Management of Adults with Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin. Infect. Dis. 2016, 63, e61–e111. [Google Scholar] [CrossRef] [PubMed]
- Robicsek, A.; Suseno, M.; Beaumont, J.L.; Thomson, R.B.; Peterson, L.R. Prediction of Methicillin-Resistant Staphylococcus aureus Involvement in Disease Sites by Concomitant Nasal Sampling. J. Clin. Microbiol. 2008, 46, 588–592. [Google Scholar] [CrossRef] [PubMed]
- Dangerfield, B.; Chung, A.; Webb, B.; Seville, M.T. Predictive value of methicillin-resistant Staphylococcus aureus (MRSA) nasal swab PCR assay for MRSA pneumonia. Antimicrob. Agents Chemother. 2014, 58, 859–864. [Google Scholar] [CrossRef] [PubMed]
- Giancola, S.E.; Nguyen, A.T.; Le, B.; Ahmed, O.; Higgins, C.; Sizemore, J.A.; Orwig, K.W. Clinical utility of a nasal swab methicillin-resistant Staphylococcus aureus polymerase chain reaction test in intensive and intermediate care unit patients with pneumonia. Diagn. Microbiol. Infect. Dis. 2016, 86, 307–310. [Google Scholar] [CrossRef]
- Smith, M.N.; Erdman, M.J.; Ferreira, J.A.; Aldridge, P.; Jankowski, C.A. Clinical utility of methicillin-resistant Staphylococcus aureus nasal polymerase chain reaction assay in critically ill patients with nosocomial pneumonia. J. Crit. Care. 2017, 38, 168–171. [Google Scholar] [CrossRef]
- Parente, D.M.; Cunha, C.B.; Mylonakis, E.; Timbrook, T.T. The Clinical Utility of Methicillin-Resistant Staphylococcus aureus (MRSA) Nasal Screening to Rule Out MRSA Pneumonia: A Diagnostic Meta-analysis with Antimicrobial Stewardship Implications. Clin. Infect. Dis. 2018, 67, 1–7. [Google Scholar] [CrossRef]
- Baby, N.; Faust, A.C.; Smith, T.; Sheperd, L.A.; Knoll, L.; Goodman, E.L. Nasal Methicillin-Resistant Staphylococcus aureus (MRSA) PCR Testing Reduces the Duration of MRSA-Targeted Therapy in Patients with Suspected MRSA Pneumonia. Antimicrob. Agents Chemother. 2017, 61, e02432-16. [Google Scholar] [CrossRef]
- Dureau, A.F.; Duclos, G.; Antonini, F.; Boumaza, D.; Cassir, N.; Alingrin, J.; Leone, M. Rapid diagnostic test and use of antibiotic against methicillin-resistant Staphylococcus aureus in adult intensive care unit. Eur. J. Clin. Microbiol. Infect. Dis. 2017, 36, 267–272. [Google Scholar] [CrossRef]
- Dunaway, S.; Orwig, K.W.; Arbogast, Z.Q.; Myers, Z.L.; Sizemore, J.A.; Giancola, S.E. Evaluation of a pharmacy-driven methicillin-resistant Staphylococcus aureus surveillance protocol in pneumonia. Int. J. Clin. Pharm. 2018, 40, 526–532. [Google Scholar] [CrossRef]
- Dadzie, P.; Dietrich, T.; Ashurst, J. Impact of a Pharmacist-driven Methicillin-resistant Staphylococcus aureus Polymerase Chain Reaction Nasal Swab Protocol on the De-escalation of Empiric Vancomycin in Patients with Pneumonia in a Rural Healthcare Setting. Cureus 2019, 11, e6378. [Google Scholar] [CrossRef] [PubMed]
- Woolever, N.L.; Schomberg, R.J.; Cai, S.; Dierkhising, R.A.; Dababneh, A.S.; Kujak, R.C. Pharmacist-Driven MRSA Nasal PCR Screening and the Duration of Empirical Vancomycin Therapy for Suspected MRSA Respiratory Tract Infections. Mayo Clin. Proc. Innov. Qual. Outcomes 2020, 4, 550–556. [Google Scholar] [CrossRef] [PubMed]
- Diep, C.; Meng, L.; Pourali, S.; Hitchcock, M.M.; Alegria, W.; Swayngim, R.; Holubar, M. Effect of rapid methicillin-resistant Staphylococcus aureus nasal polymerase chain reaction screening on vancomycin use in the intensive care unit. Am. J. Health Syst. Pharm. 2021, 78, 2236–2244. [Google Scholar] [CrossRef] [PubMed]
- Pham, S.N.; Sturm, A.C.; Jacoby, J.S.; Egwuatu, N.E.; Dumkow, L.E. Impact of a Pharmacist-Driven MRSA Nasal PCR Protocol on Pneumonia Therapy. Hosp. Pharm. 2021, 56, 221–227. [Google Scholar] [CrossRef]
- Dadgostar, P. Antimicrobial Resistance: Implications and Costs. Infect. Drug. Resist. 2019, 12, 3903–3910. [Google Scholar] [CrossRef]
- Shehab, N.; Patel, P.R.; Srinivasan, A.; Budnitz, D.S. Emergency department visits for antibiotic-associated adverse events. Clin. Infect. Dis. 2008, 47, 735–743. [Google Scholar] [CrossRef]
- WHO Access, Watch, Reserve (AWaRe) Classification of Antibiotics for Evaluation and Monitoring of Use, 2021. Geneva: World Health Organization; 2021 (WHO/MHP/HPS/EML/2021.04). Licence: CC BY-NC-SA 3.0 IGO. Available online: https://www.who.int/publications/i/item/2021-aware-classification (accessed on 19 April 2023).
- Shariati, A.; Dadashi, M.; Moghadam, M.T.; Van Belkum, A.; Yaslianifard, S.; Darban-Sarokhalil, D. Global prevalence and distribution of vancomycin intermediate Staphylococcus aureus clinical isolates: A systematic review and meta-analysis. Sci. Rep. 2020, 10, 12689. [Google Scholar] [CrossRef]
- Jones, B.E.; Ying, J.; Stevens, V.; Haroldsen, C.; He, T.; Nevers, M.; Samore, M.H. Empirical Anti-MRSA vs Standard Antibiotic Therapy and Risk of 30-Day Mortality in Patients Hospitalized for Pneumonia. JAMA Intern. Med. 2020, 180, 552. [Google Scholar] [CrossRef]
- Carey, G.B.; Holleck, J.L.; Ein Alshaeba, S.; Jayakrishnan, R.; Gordon, K.S.; Grimshaw, A.A.; Gunderson, C.G. Estimated mortality with early empirical antibiotic coverage of methicillin-resistant Staphylococcus aureus in hospitalized patients with bacterial infections: A systematic review and meta-analysis. J. Antimicrob. Chemother. 2023, 78, 1150–1159. [Google Scholar] [CrossRef]
- Acuna-Villaorduna, C.; Branch-Elliman, W.; Strymish, J.; Gupta, K. Active identification of patients who are methicillin-resistant Staphylococcus aureus colonized is not associated with longer duration of vancomycin therapy. Am. J. Infect. Control 2017, 45, 1081–1085. [Google Scholar] [CrossRef]
- De Jong, E.; De Jong, A.S.; Bartels, C.J.M.; Van Der Rijt-Van Den Biggelaar, C.; Melchers, W.J.G.; Sturm, P.D.J. Clinical and laboratory evaluation of a real-time PCR for Clostridium difficile toxin A and B genes. Eur. J. Clin. Microbiol. Infect. Dis. 2012, 31, 2219–2225. [Google Scholar] [CrossRef] [PubMed]
- Wright, W.F.; Overman, S.B.; Ribes, J.A. (1–3)-β-D-Glucan Assay: A Review of its Laboratory and Clinical Application. Lab. Med. 2011, 42, 679–685. [Google Scholar] [CrossRef]
Characteristics | All Patients (n = 52) |
---|---|
Age in years, median (IQR) | 61 (49.25–71.65) |
Race, n (%) | |
Caucasian | 33 (63.5) |
African American | 17 (32.7) |
Hispanic | 2 (3.8) |
Sex, n (%) | |
Male | 33 (63.5) |
Female | 19 (36.5) |
Hospital length of stay in days, median (IQR) | 10 (6–19) |
Treatment location, n (%) | |
Non-ICU | 26 (50) |
ICU | 26 (50) |
Indication for anti-MRSA therapy, n (%) | |
Respiratory infection | 37 (71.2) |
CAP | 28 (53.8) |
HAP | 8 (15.4) |
VAP | 1 (1.9) |
Non-respiratory infection | 15 (30.8) |
Sepsis | 4 (7.7) |
Bacteremia | 2 (3.8) |
Skin and soft tissue infection | 5 (9.6) |
Urinary tract infection | 3 (5.8) |
Osteomyelitis | 1 (1.9) |
Respiratory culture obtained, n (%) | 24 (46.2) |
Culture specimen, n (%) | |
Sputum | 5 (20.8) |
Bronchoalveolar lavage (BAL) | 17 (70.8) |
Tracheal aspirate | 2 (8.3) |
Group | Total Duration of Anti-MRSA Therapy in Days, Median (IQR) | Duration of Anti-MRSA Therapy Following MRSA PCR Result in Days, Median (IQR) |
---|---|---|
All patients (n = 52) | 5 (3–6) | 4 (3–5.25) |
Treatment location | ||
Non-ICU (n = 26) | 4 (3–6.25) | 4 (2.75–6) |
ICU (n = 26) | 5 (3–5.25) | 4 (3–5) |
Type of pneumonia | ||
CAP (n = 19) | 4 (2.25–5) | 4 (2.25–5) |
HAP (n = 7) | 7 (5.25–7) | 6 (4.25–10.75) |
VAP (n = 1) | 3 (n/a) | 3 (n/a) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Pelham, M.; Ganter, M.; Eudy, J.; Anderson, D.T. Evaluation of Anti-Methicillin-Resistant Staphylococcus aureus (MRSA) Prescribing Habits in Patients with a Positive MRSA Nasal Swab in the Absence of Positive Cultures. Pharmacy 2023, 11, 81. https://doi.org/10.3390/pharmacy11030081
Pelham M, Ganter M, Eudy J, Anderson DT. Evaluation of Anti-Methicillin-Resistant Staphylococcus aureus (MRSA) Prescribing Habits in Patients with a Positive MRSA Nasal Swab in the Absence of Positive Cultures. Pharmacy. 2023; 11(3):81. https://doi.org/10.3390/pharmacy11030081
Chicago/Turabian StylePelham, Madeline, Madeline Ganter, Joshua Eudy, and Daniel T. Anderson. 2023. "Evaluation of Anti-Methicillin-Resistant Staphylococcus aureus (MRSA) Prescribing Habits in Patients with a Positive MRSA Nasal Swab in the Absence of Positive Cultures" Pharmacy 11, no. 3: 81. https://doi.org/10.3390/pharmacy11030081